What biopharma needs to know about the Inflation Reduction Act
The ultimate resource on the IRA
On August 16, 2022, President Joe Biden signed the Inflation Reduction Act (IRA) into law. Significant changes are coming regarding drug pricing and payment in the United States.
There are a number of implications that biopharma companies will need to consider across the full drug discovery, development, and commercialization spectrum as they adapt to this U.S. marketplace reality.
Explore our insights and perspectives on the key elements of the new law and tap into our comprehensive understanding of the IRA. Contact us to start a conversation and our health policy and government affairs experts can guide you to the right solutions to help you navigate the IRA.
Inflation Reduction Act Insights
First 10 drugs for Medicare price negotiation announced under IRA
For the first time in history, Medicare will directly negotiate a maximum fair price of select high expenditure, single source drugs without a generic or biosimilar equivalent. Read more to see the 10 drugs include the price negotiations.
Available on-demand webinar: IRA Update: Key considerations for 2023
Don't miss out on this valuable opportunity to learn about key dates, the implementation timeline, and the potential impacts the Inflation Reduction Act (IRA) will have on the biopharma industry. Download the webinar to learn more.
Policy updates: From the Inflation Reduction Act to the Enhancing Oncology Model
Cencora’s U.S. Policy and Advocacy team provides a summary of the newly passed Inflation Reduction Act of 2022, and Christopher Brunner, Senior Regional Manager of Oncology Supply at Cencora, walks us through the upcoming Enhancing Oncology Model and steps practices can take to ensure a strong start in 2023.
How will the Inflation Reduction Act affect the biopharma industry?
The Inflation Reduction Act (IRA) of 2022 will have a substantial impact on biopharma companies. It is the most significant healthcare legislation since the Affordable Care Act (ACA) in 2010. The biopharma industry should be aware that the IRA will affect drug pricing, reimbursement strategies, and patient assistance program designs.
